<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758481</url>
  </required_header>
  <id_info>
    <org_study_id>RVO-FNOs/2020-22</org_study_id>
    <nct_id>NCT04758481</nct_id>
  </id_info>
  <brief_title>Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer</brief_title>
  <official_title>Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy of All Body Locations With the Disease at 3 Months After First Line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer, Prior to Maintenance Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is the main cause of death among cancer diseases, in the Czech Republic, as well&#xD;
      as worldwide. Non-small cell lung cancer (NSCLC) is responsible for more than 80% of deaths&#xD;
      among cancer patients. Bronchogenic carcinoma is the reason of death of almost 5.500 cases&#xD;
      every year in the Czech Republic, the mortality/incidence ration varies around 85%. The main&#xD;
      cause for these unfavorable findings is the late detection of the carcinoma in late stages&#xD;
      only (III and IV), when a long-term control of the disease is exceptional. Chemotherapy is&#xD;
      able to prolong the life of patients with NSCLC by less than one year on average, that is why&#xD;
      new treatment approaches are being examined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The basic treatment modality of lung cancer is radiotherapy, which has a proven therapeutic&#xD;
      benefit in radical and palliative indications in up to 76% of all patients. Stereotactic&#xD;
      robotic radiotherapy reaches maximum precision due to the precise definition of the target&#xD;
      volume. In some localities, management with images has been solved using modern software&#xD;
      instruments, which are able to visualize the tumor and monitor it during the whole course of&#xD;
      respiratory cycle. This is directly associated with minimizing radiation of healthy tissues,&#xD;
      especially the healthy lung parenchyma. In order to define predictive factors of survival of&#xD;
      cancer patients, it is necessary to use molecular markers.&#xD;
&#xD;
      The aim of the study is to verify the feasibility of consolidation SBRT (Stereotactic Body&#xD;
      RadioTherapy) - CyberKnife, with subsequent maintenance chemotherapy in patients with stage&#xD;
      IV NSCLC, with max. 10 metastatic nidi. The main focus of the study will be on assessment of&#xD;
      combination treatment toxicity.&#xD;
&#xD;
      The project is a phase I/II non-randomized clinical trial. Patients with stage IV NSCLC will&#xD;
      be treated with 2-4 cycles of chemotherapy - platinum doublet (cisplatinum -&#xD;
      cDDP/carboplatinum - CBDCA + Pemetrexed/navelibne - NVB). In cases when disease stabilization&#xD;
      (SD)/partial resection (PR) will be achieved, based upon restaging examinations (CT),&#xD;
      radiotherapy (RT) of the primary tumour will follow, with lymphadenopathy and SBRT of all&#xD;
      metastatic nidi (max. 10 intra- or extracranial metastases). Standard fractionation schemes&#xD;
      for RT and SBRT will be used (RT 40-50 Gy/16-20 fractions, SBRT 30 Gy/1 fractionation, 50-60&#xD;
      Gy/3-5 fractionations). At 3-6 weeks after the end of RT, maintenance treatment will be&#xD;
      initiated in all patients treated with Peterexed. Regular restaging examinations are planned&#xD;
      every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 4, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a non-randomised study with the primary intent to treat patients with NSCLC</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The study is open label, no masking is being used.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Acute and late toxicity</measure>
    <time_frame>every 3 months, throughout the study duration, up to 32 months in total</time_frame>
    <description>Acute and late toxicity of the combination therapy will be observed (according to Common Terminology for Clinical Adverse Event (CTCAE, version 5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>every 3 months</time_frame>
    <description>Progression-free survival will be observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 3 months, throughout the study duration, up to 32 months in total</time_frame>
    <description>Overall survival will be observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Share of nidi under local control</measure>
    <time_frame>every 3 months, throughout the study duration, up to 32 months in total</time_frame>
    <description>The share of nidi under local control will be observed (in per cent/total number of nidi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to new nidus formation</measure>
    <time_frame>every 3 months, throughout the study duration, up to 32 months in total</time_frame>
    <description>The time to new nidus formation will be observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of maintenance chemotherapy</measure>
    <time_frame>every 3 months, throughout the study duration, up to 32 months in total</time_frame>
    <description>The duration of maintenance chemotherapy will be observed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Primary tumour radiotherapy + stereotactic body radiotherapy + maintenance radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients, in whom disease stabilisation/partial regression will be achieved, will undergo primary tumour radiotherapy and stereotactic body radiotherapy, followed with maintenance radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>primary tumour radiotherapy</intervention_name>
    <description>The study subjects will undergo primary tumour radiotherapy.</description>
    <arm_group_label>Primary tumour radiotherapy + stereotactic body radiotherapy + maintenance radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiotherapy</intervention_name>
    <description>The study subjects will undergo stereotactic body radiotherapy.</description>
    <arm_group_label>Primary tumour radiotherapy + stereotactic body radiotherapy + maintenance radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>maintenance radiotherapy</intervention_name>
    <description>The study subjects will undergo maintenance radiotherapy.</description>
    <arm_group_label>Primary tumour radiotherapy + stereotactic body radiotherapy + maintenance radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with previously untreated, non-resectable, stage IV NSCLC verified with&#xD;
             histology or cytology (according to American Joint Committee on Cancer Version 8).&#xD;
&#xD;
          -  Patients must undergo 2-4 cycles of first-line chemotherapy, with the effect of&#xD;
             disease stabilization or partial response.&#xD;
&#xD;
          -  Patients over 18 years of age.&#xD;
&#xD;
          -  Patients with measureable disease (on CT, PET/CT, MRI).&#xD;
&#xD;
          -  Patients with 3-10 extracranial/intracranial lesions confirmed on CT, PET/CT, MRI,&#xD;
             max. 4 weeks prior to start of SBRT.&#xD;
&#xD;
          -  Max. 10 irradiated volumes (primary tumour + lymphadenopathy in one volume, if&#xD;
             technically feasible).&#xD;
&#xD;
          -  Performance status (PS) 0-2 according to ECOG. Assessment of PS max. 7 days prior to&#xD;
             start of treatment.&#xD;
&#xD;
          -  AST, ALT &amp; ALP ≤ 2.5x norm. Total bilirubin must be within the normal range. 9. Normal&#xD;
             function of bone marrow - Adiponectin ≥ 1.5, Haemoglobin ≥ 100, thrombo ≥ 100.&#xD;
&#xD;
          -  Serum creatinine ≤1.5x norm.&#xD;
&#xD;
          -  The entry laboratory tests must not be older than 14 days prior to start of treatment.&#xD;
&#xD;
          -  Negative pregnancy test and use of contraception in women of childbearing age.&#xD;
&#xD;
          -  Patients undergoing SBRT for pulmonary nidi must undergo entry spirometry with the&#xD;
             value FEV1 (forced expiratory volume in 1 second) ≥ 1L.&#xD;
&#xD;
          -  Patients must sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with small-cell lung cancer or with mixed aetiology with SCLC.&#xD;
&#xD;
          -  Serious ongoing infections.&#xD;
&#xD;
          -  Patients with a history of haematopoiesis disorders.&#xD;
&#xD;
          -  Weight loss exceeding 10% within the last 3 months.&#xD;
&#xD;
          -  Patients with skin metastases of NSCLC.&#xD;
&#xD;
          -  Patients treated for other malignity within the last 5 years&#xD;
&#xD;
          -  Patients with more than 10 extracranial/intracranial metastases.&#xD;
&#xD;
          -  Malignant fluidothorax &gt; 1 cm prior to start of treatment.&#xD;
&#xD;
          -  Patients treated with targeted treatment for EGFR mutation or EML-4-ALK translocation&#xD;
             in the 1st-line (Erlotinib, Gefitinib, Afatinib, Crizotinib, …).&#xD;
&#xD;
          -  Patients treated with immunotherapy (anti-PD-1, anti-PD-L1 or anti-PD-L2, anti CTLA-4,&#xD;
             …).&#xD;
&#xD;
          -  Participation in another clinical trial within the last month before the start of&#xD;
             NSCLC treatment.&#xD;
&#xD;
          -  Inability to cooperate or comply with the study protocol.&#xD;
&#xD;
          -  Decision of the patient to discontinue participation in the study.&#xD;
&#xD;
          -  Pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tereza Paračková, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiří Hynčica</last_name>
    <phone>0042059737</phone>
    <phone_ext>2587</phone_ext>
    <email>jiri.hyncica@fno.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiří Hynčica</last_name>
      <phone>0042059773</phone>
      <phone_ext>2587</phone_ext>
      <email>jiri.hyncica@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Tereza Paračková, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavel Dvořák, Ing.,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukáš Knybel, Ing.,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamila Resová, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol. 2010 Jul;5(7):1091-9. doi: 10.1097/JTO.0b013e3181de7143. Review.</citation>
    <PMID>20479693</PMID>
  </reference>
  <reference>
    <citation>Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Karasawa K, Hayakawa K, Niibe Y, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Kozuka T, Arimoto T, Hara R, Itami J, Araki T. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1352-8. doi: 10.1016/j.ijrobp.2009.07.1751. Epub 2010 Jul 16.</citation>
    <PMID>20638194</PMID>
  </reference>
  <reference>
    <citation>Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011 Nov;101(2):255-9. doi: 10.1016/j.radonc.2011.05.033.</citation>
    <PMID>21641064</PMID>
  </reference>
  <reference>
    <citation>Collen C, Christian N, Schallier D, Meysman M, Duchateau M, Storme G, De Ridder M. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol. 2014 Oct;25(10):1954-1959. doi: 10.1093/annonc/mdu370. Epub 2014 Aug 11.</citation>
    <PMID>25114022</PMID>
  </reference>
  <reference>
    <citation>Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, Mizowaki T, Yano S, Hiraoka M. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):398-403. doi: 10.1016/j.ijrobp.2008.01.002. Epub 2008 Apr 18.</citation>
    <PMID>18374506</PMID>
  </reference>
  <reference>
    <citation>Guerrero E, Ahmed M. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer. Lung Cancer. 2016 Feb;92:22-8. doi: 10.1016/j.lungcan.2015.11.015. Epub 2015 Dec 2. Review.</citation>
    <PMID>26775592</PMID>
  </reference>
  <reference>
    <citation>Oh D, Ahn YC, Seo JM, Shin EH, Park HC, Lim DH, Pyo H. Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol. 2012 May;51(5):596-602. doi: 10.3109/0284186X.2012.681698. Epub 2012 May 1.</citation>
    <PMID>22548366</PMID>
  </reference>
  <reference>
    <citation>Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, Joyce N, Schell MC, Milano MT. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis. 2014 Apr;6(4):369-74. doi: 10.3978/j.issn.2072-1439.2013.12.03.</citation>
    <PMID>24688781</PMID>
  </reference>
  <reference>
    <citation>Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6(12):e28650. doi: 10.1371/journal.pone.0028650. Epub 2011 Dec 13.</citation>
    <PMID>22174856</PMID>
  </reference>
  <reference>
    <citation>Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 Jul 15;122(14):2242-50. doi: 10.1002/cncr.30058. Epub 2016 May 20.</citation>
    <PMID>27206146</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>stereotactic body radiotherapy</keyword>
  <keyword>CyberKnife</keyword>
  <keyword>maintenance radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share the individual participant data with other researchers; the data may be provided upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

